Abstract:Cystic fibrosis (CF) is an autosomal-recessive condition that is caused by a mutation in the CFTR gene (1) . As CF patients' prognoses are improving due to highly effective modulator therapy, (HEMT) managing comorbidities such as bone disease is pertinent. This could be exacerbated by vitamin D insufficiency which has been estimated to be as high as 98% in adults with CF (1) . This systematic review aimed to evaluate the efficacy and safety of high-dose cholecalciferol (vitamin D 3 ) supplementation in correcting inadequate serum 25-hydroxyvitamin D (serum 25(OH)D) concentration in adults with CF. The systematic search included studies that examined the impact of high-dose cholecalciferol on serum 25(OH)D concentration. Eligible RCTs included study designs that involved adults with CF and a high-dose cholecalciferol supplementation protocol (defined as any dose above basal) compared with basal doses (800IU-1000IU/day)/no supplementation. A systematic search was conducted and a meta-analysis of RCTs was produced to calculate the change in serum 25(OH)D concentration in the intervention group in comparison to control as the primary outcome measure. The systematic search yielded five RCTs that were collated and analysed. The results of the metaanalysis demonstrated that the high-dose cholecalciferol group and control group achieved a serum 25(OH)D concentration of 40.19ng/ml ± 10.21ng/ml and 28.50ng/ml ± 7.35ng/ml respectively (p 30ng/ml). A high heterogeneity was observed across the studies (I2 = 87%) (2,3) . Doses varied from daily supplementation of 1,700IU to a 250,000IU single dose. There were minimal adverse effects reported in the RCTs from high-dose cholecalciferol and there were no instances of hypervitaminosis D or hypercalcaemia reported (3) . The results infer the effectiveness of high-dose cholecalciferol in correcting low serum 25(OH)D concentration in adults with CF. The most effective regimen identified was a single weekly dose of 50,000IU for 12 weeks, which achieved serum 25(OH)D concentration of 45.91ng/ml ± 11.24ng/ml (control: 23.61ng/ml ± 4.37ng/ml) (p<0.01) after a 12-week intervention (2) . The key findings suggest that annual monitoring of serum 25(OH)D concentration would be beneficial with a tailored high-dose cholecalciferol protocol. A high level of heterogeneity was observed across the studies, with small sample sizes, meaning a larger multi-centre, multi-nation RCT study that considers the context of advances in HEMT should be conducted to corroborate the results before implementation into clinical guidelines. High-dose cholecalciferol supplementation is an effective and safe method to increase serum 25(OH)D concentration in adults with CF that may lead to improved bone health outcomes. More studies are required before revising current vitamin D supplementation guidelines. Future research should focus on establishing dosing guidelines to optimise vitamin D status, exploring the longterm health outcomes of sustained adequate serum 25(OH)D concentration.

Effect of cholecalciferol versus calcifediol on serum 25(OH)D concentrations: a systematic review with meta-analysis

Effect of Low-Dose Vitamin D Supplementation on Serum 25(OH)D in School Children and White-Collar Workers.

The problem of vitamin D deficiency among the population and the efficacy of drugs in increasing its level

Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis

Calcifediol (25OH Vitamin D3) Deficiency: A Risk Factor from Early to Old Age

Real-world effectiveness and safety of combined calcium 600 mg and cholecalciferol 2000 IU for treating vitamin d deficiency: Results from a nationwide study with focus in osteoporosis

Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study

Safety and effects of calcifediol 0.266 milligrams soft capsules monthly and cholecalciferol 25000 international units monthly in osteoporotic women undergoing therapy with alendronate: a cross-sectional study

Comparison of Oral Vitamin D2 and Vitamin D3 Supplementation in Raising Serum 25-Hydroxy Vitamin D Status in Pediatric Patients

Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial

Comparison of the Effects of Cholecalciferol and Calcitriol on Calcium Metabolism and Bone Turnover in Chinese Postmenopausal Women with Vitamin D Insufficiency

Effects of Oral Cholecalciferol on Serum 25-Hydroxyvitamin D Level, Bone Mineral Density and Lower Extremity Function in Postmenopausal Women with Vitamin D Insufficiency

The health effects of vitamin D supplementation: evidence from human studies

A systematic review to evaluate the efficacy and safety of high-dose vitamin D supplementation in adults with cystic fibrosis

Vitamin D Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Observational Studies and Randomized Controlled Trials

The effect of vitamin D2 supplementation on vitamin D levels in humans: A time and dose–response meta-analysis of randomized controlled trials

Efficacy of weekly versus daily cholecalciferol for repleting serum vitamin D (25(OH)D) deficiency: A systematic review and meta‐analysis of randomized controlled trials

The Impact and Efficacy of Vitamin D Fortification

Correlation between serum 1,25-dihydroxyvitamin D and 25-hydroxyvitamin D in response to analytical procedures; a systematic review and meta-analysis

Effects of Intermittent Overload Doses of Oral Vitamin D3 on Serum 25(OH)D Concentrations and the Incidence Rates of Fractures, Falls, and Mortality in Elderly Individuals: A Systematic Review and Meta-Analysis

Impact of BMI on serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D with calcifediol supplementation in young adults: a longitudinal study